Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
0.501
-0.021 (-4.04%)
At close: Mar 6, 2026, 4:00 PM EST
0.502
+0.001 (0.26%)
After-hours: Mar 6, 2026, 7:49 PM EST
Gossamer Bio Employees
As of December 31, 2024, Gossamer Bio had 145 total employees, including 144 full-time and 1 part-time employees. The number of employees increased by 10 or 7.41% compared to the previous year.
Employees
145
Change (1Y)
10
Growth (1Y)
7.41%
Revenue / Employee
$303,800
Profits / Employee
-$1,076,972
Market Cap
115.89M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Codexis | 188 |
| Inovio Pharmaceuticals | 134 |
| Spero Therapeutics | 32 |
| Cardiff Oncology | 31 |
| Oncolytics Biotech | 28 |
| Genelux | 24 |
| Black Diamond Therapeutics | 24 |
| Coya Therapeutics | 8 |
GOSS News
- 2 days ago - Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1 - Benzinga
- 6 days ago - GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 12 days ago - Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension Transcript - Seeking Alpha
- 12 days ago - BREAKING: Gossamer Bio Investors Should Contact Block & Leviton to Potentially Recover Losses After Shares Fall Over 75% - GlobeNewsWire
- 12 days ago - Gossamer Bio Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 12 days ago - Gossamer Bio Plans FDA Talks After Narrow Miss In Key Pivotal Study, Stock Sinks - Benzinga
- 12 days ago - Gossamer Bio's experimental lung condition drug fails in late-stage trial - Reuters
- 12 days ago - Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension - Business Wire